Moderna and Pfizer-BioNTech shots could be given to the youngest kids as early as June 21.

US adults are now only eligible for the vaccine under certain circumstances.

The vaccine’s effectiveness in children ages 5 to 11 rapidly declined over the course of a month, according to new research that looked at the health outcomes of hundreds of thousands of children in New York during the Omicron surge.

Given within three days of symptom onset, the pill combination was nearly 90 percent effective at preventing high-risk patients from developing severe illness in a clinical study.

His work contributed to the development of the drug Xalatan, a treatment for glaucoma.

Health Canada has given the single COVID-19 shot the official greenlight for use in people 18 and older.

Health authorities in both countries announced that people under certain age cutoffs are now ineligible for the Spikevax COVID-19 shot due to its association with heart inflammation.

Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna’s elicits a stronger immune response and might be better at preventing breakthrough infections.  

The milestone marks the first fully-approved COVID-19 vaccine in the United States.

The organization implored nations to wait on booster shots until the global vaccination rate increases, but several of the world’s more well-off countries have expressed their intentions to offer them regardless.

A study looks beyond T and B cell responses to show how the Pfizer COVID-19 vaccine elicits a strong innate immune response.

Scientists at the US CDC report no red flags in a preliminary analysis of the safety of Pfizer/BioNTech’s and Moderna’s mRNA-based immunizations among expectant mothers.

The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.

In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.

Two preliminary reports from the UK provide real-world evidence in support of the Pfizer/BioNTech and Oxford-AstraZeneca vaccines.

Preliminary results from an Israel-based study suggest that one dose of the vaccine reduces infectiousness—a key factor in slowing virus spread.